{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:29Z","timestamp":1793155709359,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002248","name":"National Multiple Sclerosis Society Michigan Chapter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002248","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jbo.2022.100416","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T13:07:27Z","timestamp":1644239247000},"page":"100416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval"],"prefix":"10.1016","volume":"33","author":[{"given":"Benoit","family":"Cadieux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Jafarinasabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Stopeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0005","first-page":"1327","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"von Moos","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"20","key":"10.1016\/j.jbo.2022.100416_b0010","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jbo.2022.100416_b0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"8","key":"10.1016\/j.jbo.2022.100416_b0020","doi-asserted-by":"crossref","first-page":"a031286","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple myeloma and bone: the fatal interaction","volume":"8","author":"Marino","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/03007995.2018.1532884","article-title":"Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population","volume":"35","author":"Bhowmik","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.lungcan.2014.08.022","article-title":"Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study","volume":"86","author":"Cetin","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2022.100416_b0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-11-29","article-title":"Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark","volume":"11","author":"Jensen","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2022.100416_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101628","article-title":"Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data","volume":"63","author":"Parry","year":"2019","journal-title":"Cancer Epidemiol."},{"issue":"6","key":"10.1016\/j.jbo.2022.100416_b0050","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/13696998.2018.1457531","article-title":"Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database","volume":"21","author":"Bhowmik","year":"2018","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2022.100416_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2018.100215","article-title":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data","volume":"14","author":"Kim","year":"2019","journal-title":"J. Bone Oncol."},{"issue":"16","key":"10.1016\/j.jbo.2022.100416_b0060","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2022.100416_b0065","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1097\/01.blo0000092979.12414.54","article-title":"Biochemical markers and skeletal metastases","volume":"415","author":"Demers","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"5","key":"10.1016\/j.jbo.2022.100416_b0070","first-page":"496","article-title":"Hypercalcemia of malignancy","volume":"9","author":"Feldenzer","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"issue":"22","key":"10.1016\/j.jbo.2022.100416_b0075","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clon.2005.06.016","article-title":"Quality of life and symptom end points in palliative bone metastases trials","volume":"18","author":"Chow","year":"2006","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0085","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3111\/13696998.2014.975232","article-title":"Short-term disability in solid tumor patients with bone metastases and skeletal-related events","volume":"18","author":"Qian","year":"2015","journal-title":"J. Med. Econ."},{"issue":"9","key":"10.1016\/j.jbo.2022.100416_b0090","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jbo.2022.100416_b0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jbo.2022.100416_b0100","unstructured":"Zometa\u00ae, zoledronic acid, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2018."},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2022.100416_b0110","unstructured":"Aredia\u00ae, pamidronate disodium, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2012."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jbo.2016.03.002","article-title":"Bone targeted treatments in cancer - the story so far","volume":"5","author":"Coleman","year":"2016","journal-title":"J. Bone Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/SPC.0b013e328356062e","article-title":"Renal complications from bisphosphonate treatment","volume":"6","author":"Hirschberg","year":"2012","journal-title":"Curr. Opin. Support. Palliat. Care"},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1634\/theoncologist.2010-0154","article-title":"The role of RANK-ligand inhibition in cancer: the story of denosumab","volume":"16","author":"Castellano","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2022.100416_b0135","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3389\/fonc.2020.01283","article-title":"Targeting the RANKL\/RANK\/OPG axis for cancer therapy","volume":"10","author":"Ming","year":"2020","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.jbo.2022.100416_b0140","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/jbmr.3175","article-title":"Bone formation is coupled to resorption via suppression of sclerostin expression by osteoclasts","volume":"32","author":"Koide","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.jbo.2022.100416_b0145","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.jbo.2022.100416_b0150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/109158180302200512","article-title":"A toxicity profile of osteoprotegerin in the cynomolgus monkey","volume":"22","author":"Smith","year":"2003","journal-title":"Int. J. Toxicol."},{"issue":"7","key":"10.1016\/j.jbo.2022.100416_b0155","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"28","key":"10.1016\/j.jbo.2022.100416_b0160","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2022.100416_b0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","article-title":"Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours","volume":"51","author":"Gibiansky","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.jbo.2022.100416_b0170","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"20","key":"10.1016\/j.jbo.2022.100416_b0175","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12355","article-title":"The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review","volume":"78","author":"Sohn","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"16","key":"10.1016\/j.jbo.2022.100416_b0185","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2022.100416_b0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"35","key":"10.1016\/j.jbo.2022.100416_b0195","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9768","key":"10.1016\/j.jbo.2022.100416_b0200","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jbo.2022.100416_b0205","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11096-020-01105-1","article-title":"Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis","volume":"43","author":"Chen","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.jbo.2022.100416_b0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbo.2017.09.003","article-title":"The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials","volume":"9","author":"Zhang","year":"2017","journal-title":"J. Bone Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2022.100416_b0220","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3892\/ol.2014.1982","article-title":"Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials","volume":"7","author":"Wang","year":"2014","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.jbo.2022.100416_b0225","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2022.100416_b0230","doi-asserted-by":"crossref","unstructured":"N. Sathiakumar, E. Delzell, M.A. Morrisey, C. Falkson, M. Yong, V. Chia, J. Blackburn, T. Arora, I. Brill, M.L. Kilgore, Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006, Breast Cancer Res. Treat. 131(1) (2012) 231-238.","DOI":"10.1007\/s10549-011-1721-x"},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0235","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jbo.2013.01.002","article-title":"Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-an exploratory analysis of placebo-controlled trials","volume":"2","author":"Coleman","year":"2013","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","article-title":"Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer","volume":"68","author":"Fizazi","year":"2015","journal-title":"Eur. Urol."},{"issue":"23","key":"10.1016\/j.jbo.2022.100416_b0250","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"35","key":"10.1016\/j.jbo.2022.100416_b0255","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jbo.2022.100416_b0260","first-page":"3497","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Support. Care Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2022.100416_b0265","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.jbo.2022.100416_b0270","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0275","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2022.100416_b0280","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cam4.403","article-title":"Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States","volume":"4","author":"Arellano","year":"2015","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0285","article-title":"Medication-related osteonecrosis of the jaw: a review","volume":"12","author":"AlDhalaan","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0290","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2022.100416_b0295","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2022.100416_b0300","first-page":"4763","article-title":"Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases","volume":"29","author":"Ikesue","year":"2021","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.jbo.2022.100416_b0305","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.jbo.2022.100416_b0310","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2022.100416_b0315","unstructured":"XGEVA\u00ae, denosumab, Amgen Inc., Thousand Oaks, CA, 2020."},{"issue":"13","key":"10.1016\/j.jbo.2022.100416_b0320","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2022.100416_b0325","doi-asserted-by":"crossref","first-page":"iv528","DOI":"10.1093\/annonc\/mdu356.33","article-title":"Safety of Denosumab (Dmab) in Patients (Pts) with Stage 4 or Stage 5D Chronic Kidney Disease (Ckd)","volume":"25","author":"Block","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2022.100416_b0330","doi-asserted-by":"crossref","unstructured":"L. Tripto-Shkolnik, N. Fund, V. Rouach, G. Chodick, V. Shalev, I. Goldshtein, Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider, Bone 130 (2020) 115150.","DOI":"10.1016\/j.bone.2019.115150"},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0335","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mayocpiqo.2019.02.003","article-title":"Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale","volume":"3","author":"Tyan","year":"2019","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"issue":"12","key":"10.1016\/j.jbo.2022.100416_b0340","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0345","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2022.100416_b0350","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy","volume":"22","author":"Yang","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2022.100416_b0355","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer version 6.2020, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. (Accessed October 18 2020)."},{"key":"10.1016\/j.jbo.2022.100416_b0360","unstructured":"American Urological Association, Castration-Resistant Prostate Cancer: AUA Guideline, 2018. https:\/\/www.auanet.org\/guidelines\/prostate-cancer-castration-resistant-guideline. (Accessed June 14 2021)."},{"key":"10.1016\/j.jbo.2022.100416_b0365","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer version 2.2020, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. (Accessed October 18 2020)."},{"issue":"15","key":"10.1016\/j.jbo.2022.100416_b0370","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2022.100416_b0375","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-Small Cell Lung Cancer version 8.2020, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. (Accessed October 18 2020)."},{"key":"10.1016\/j.jbo.2022.100416_b0380","first-page":"335","article-title":"Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States","volume":"7","author":"Hernandez","year":"2015","journal-title":"Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.jbo.2022.100416_b0385","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.4360","article-title":"Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States","volume":"27","author":"Butler","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0390","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/03007995.2018.1558849","article-title":"Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States","volume":"35","author":"Henry","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.jbo.2022.100416_b0395","first-page":"2697","article-title":"Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US","volume":"22","author":"Hernandez","year":"2014","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2022.100416_b0400","first-page":"1845","article-title":"Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States","volume":"25","author":"Qian","year":"2017","journal-title":"Support. Care Cancer"},{"issue":"11","key":"10.1016\/j.jbo.2022.100416_b0405","first-page":"5223","article-title":"Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany","volume":"28","author":"Diel","year":"2020","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jbo.2022.100416_b0410","doi-asserted-by":"crossref","unstructured":"A.I. Abousaud, M.S. Barbee, C.C. Davis, S.E. Caulfield, Z. Wang, A. Boykin, B.C. Carthon, K. Gogineni, Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study, Ther. Adv. Med. Oncol. 12 (2020) 1758835920982859.","DOI":"10.1177\/1758835920982859"},{"issue":"5","key":"10.1016\/j.jbo.2022.100416_b0415","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1078155217703791","article-title":"Feasibility of extended dosing intervals of denosumab","volume":"24","author":"Kettle","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jbo.2022.100416_b0420","doi-asserted-by":"crossref","first-page":"100339","DOI":"10.1016\/j.jbo.2020.100339","article-title":"Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: a physician survey","volume":"26","author":"AlZahrani","year":"2021","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jbo.2022.100416_b0430","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.jbo.2022.100416_b0435","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00198-019-05271-5","volume":"31","author":"Yoshida","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0440","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2022.100416_b0445","doi-asserted-by":"crossref","unstructured":"F. Saad, J. Carles, S. Gillessen, A. Heidenreich, D. Heinrich, J. Gratt, J. Levy, K. Miller, S. Nilsson, O. Petrenciuc, M. Tucci, M. Wirth, J. Federhofer, J.M. O'Sullivan, I. Radium-223 International Early Access Program, Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial, Lancet Oncol. 17(9) (2016) 1306-1316.","DOI":"10.1016\/S1470-2045(16)30173-5"},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0450","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2022.100416_b0455","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","article-title":"Serum levels of total-RANKL in multiple myeloma","volume":"9","author":"Jakob","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0460","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2022.100416_b0465","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/cam4.1075","article-title":"Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States","volume":"6","author":"Qian","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.jbo.2022.100416_b0470","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Multiple Myeloma version 2.2021, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. (Accessed October 18 2020)."},{"issue":"8","key":"10.1016\/j.jbo.2022.100416_b0475","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0480","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Bone Working Group of the International Myeloma Working Group, Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0485","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jbo.2022.100416_b0490","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jbo.2022.100416_b0495","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cllc.2015.06.004","article-title":"Therapeutic potential of denosumab in patients with lung cancer: beyond prevention of skeletal complications","volume":"16","author":"De Castro","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.jbo.2022.100416_b0500","doi-asserted-by":"crossref","unstructured":"S. Peters, S. Danson, B. Hasan, U. Dafni, N. Reinmuth, M. Majem, K.G. Tournoy, M.T. Mark, M. Pless, M. Cobo, D. Rodriguez-Abreu, L. Falchero, T. Moran, A.L. Ortega Granados, I. Monnet, K. Mohorcic, B.M. Sureda, D. Betticher, I. Demedts, J.A. Macias, S. Cuffe, A. Luciani, J.G. Sanchez, A. Curioni-Fontecedro, O. Gautschi, G. Price, L. Coate, R. von Moos, C. Zielinski, M. Provencio, J. Menis, B. Ruepp, A. Pochesci, H. Roschitzki-Voser, B. Besse, M. Rabaglio, M.E.R. O'Brien, R.A. Stahel, A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR trial, J. Thorac. Oncol. 15(10) (2020) 1647-1656.","DOI":"10.1016\/j.jtho.2020.06.011"},{"issue":"7","key":"10.1016\/j.jbo.2022.100416_b0505","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jbo.2022.100416_b0510","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"REaCT investigators, A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"20","key":"10.1016\/j.jbo.2022.100416_b0515","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.3390\/ijms21207570","article-title":"The role of the RANKL\/RANK axis in the prevention and treatment of breast cancer with immune checkpoint inhibitors and anti-RANKL","volume":"21","author":"Simatou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0520","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00774-020-01182-2","article-title":"Role of RANKL in cancer development and metastasis","volume":"39","author":"Okamoto","year":"2021","journal-title":"J. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0525","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-016-4029-z","article-title":"Can we prevent BRCA1-associated breast cancer by RANKL inhibition?","volume":"161","author":"Kotsopoulos","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.jbo.2022.100416_b0530","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Austrian Breast and Colorectal Cancer Study Group, Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100416_b0535","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:26Z","timestamp":1761941966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137422000069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":107,"alternative-id":["S2212137422000069"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100416","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100416"}}